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Abstract. Doxorubicin-filled boehmite nanocontainers,
DOX@γ-AlO(OH), with a mean diameter of 40 nm and a wall thick-
ness of 10 nm are prepared via a microemulsion strategy and studied
as drug carriers for cancer treatment. Nanocontainer structure and drug
load are examined in detail based on different analytical tools. The
DOX load is optimized on highest load at lowest side effects according
to blood counts. Cell uptake, DOX-based fluorescence detection and
1 Introduction
Doxorubicin (DOX) is one of the most widely used chemo-
therapeutics to date and used for treatment of a range of tu-
mors, including liver and breast carcinoma or AIDS-related
Kaposi’s sarcoma.[1] The liposome-encapsulated form of DOX
(so-called Doxil), moreover, is an established clinical stan-
dard.[1,2] DOX has nevertheless certain disadvantages such as
high systemic toxicity (e.g. cardiotoxicity, heart arrhytmia,
neutropenia), low selectivity towards tumor cells and rapid de-
gradation in the physiological environment before reaching the
cancer cells.[3] To improve drug transport and to decrease bio-
degradability and systemic toxicity of DOX simultaneously,
nanocontainer systems have already proven to be advan-
tageous.[4] In this regard, SiO2-based mesoporous nanocontai-
ners,[5] iron oxide,[6] gold,[7] or polymer-based[8] nanocontai-
ners were studied most widely. Most of these studies, however,
are limited to in vitro experiments, and they often did not con-
sider side effects. Especially, SiO2 has been critically discussed
since recently due to its potential long-term carcinogenic ef-
fects.[9]
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systemic toxicity are evaluated based on in vitro and in vivo models.
Toxicity and activity of the DOX@AlO(OH) nanocontainers are com-
pared with non-filled AlO(OH) hollow spheres and free DOX as refer-
ences and show promising results. An orthotopic breast cancer
BALB/c mouse model validates the activity of DOX@AlO(OH) in
vivo at lower side effects than for free DOX.
Nanocontainers are typically characterized by diameters of
80 to 120 nm; in some cases even larger particles have been
described.[4–8] The DOX concentration in the nanocontainers
can be rather high and was reported with loads up to
2100 mg·g–1.[10] In general, a high concentration of doxorub-
icin is intended in order to achieve high cytotoxic effects. In
regard of uncontrolled release, biodegradation, systemic toxic-
ity and side effects,[1,3,4] however, efficient transport and re-
lease of DOX are just as important. Hence, the DOX concen-
tration should preferably be optimized on highest activity at
lowest side effects. Side effects as well as metastatic activity,
however, were barely addressed in the literature.
Often nanocontainers with mesoporous walls are used to al-
low a sufficient release of DOX after the nanocontainer having
entered single tumor cells or solid tumors.[4–6,8] A key issue
for these systems is how to “switch off” and “switch on” the
mesopores in response to biological or external stimuli. More-
over, membrane permeability, cell uptake and tumor infil-
tration are often hampered for such particles that often exceed
the nanoregime (i.e. diameter  100 nm), especially, if certain
particle agglomeration occurs as well. In this regard, nanopar-
ticles with a mean diameter of 5020 nm have been reported
as optimal in terms of tumor infiltration.[11] To address the
aforementioned issues-including DOX concentration and cyto-
toxicity, systemic toxicity and side effects, cell uptake and drug
release, targeted delivery, colloidal stability of the nanocarriers
in physiological media, etc.-chemical synthesis and materials
composition often have become more and more complex, in-
cluding multi-step synthesis and sophisticated multi-compo-
nent structures.[12]
As an alternative concept, we here suggest doxorubicin-
filled boehmite nanocontainers, DOX@γ-AlO(OH), for drug
delivery and cancer treatment, which show promising anti-
tumor and anti-metastatic activities in combination with low
side effects.
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2 Results and Discussion
2.1 Synthesis of DOX@AlO(OH) Nanocontainers
AlO(OH) hollow spheres as nanocontainers were prepared
via a microemulsion approach similar to our previous studies
(Figure 1a).[13] The essential aspect of the synthesis strategy is
related to reactants that were added to the different
phases of the water-in-oil-(w/o)-microemulsion system. Thus,
Al(sec-OC4H9)3 as a lipophilic starting material was added to
the lipophilic dispersion phase, whereas H2O as a hydrophilic
starting material was part of the polar droplet phase. As both
reactants Al(sec-OC4H9)3 and H2O only meet at the water-to-
oil phase boundary of the microemulsion, hydrolysis of the
alkoxide is restricted to this phase boundary and results in solid
AlO(OH) spheres that–at the end of the reaction–encapsulate
the water droplets (Figure 1a). According to electron micro-
scopy and dynamic light scattering, the as-prepared AlO(OH)
nanocontainers exhibit an outer diameter of 30–50 nm, a cavity
size of 20–30 nm and a wall thickness of 8–12 nm (Figure 1b–
d and Figure S1, Supporting Information). High resolution
images verify the thickness and crystallinity of the sphere wall
with lattice distances of 3.2 Å (γ-AlO(OH)/boehmite: d(120)
with 3.16 Å,[14] Figure 1b). Previous investigations have ad-
dressed the purity, crystallinity and specific surface area of the
as-prepared AlO(OH) nanocontainers in detail.[13]
Figure 1. Synthesis of doxorubicin-filled boehmite nanocontainers
(DOX@γ-AlO(OH)): (a) Scheme illustrating hollow sphere formation
and DOX encapsulation; (b–d) size and structure according to trans-
mission electron microscopy with: (b) high-resolution image of sphere
wall, (c) high-resolution image of single hollow sphere, (d) overview
image of hollow spheres.
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Encapsulation of pharmaceuticals such as DOX inside the
AlO(OH) nanocontainers is straightforward: hydrophilic drugs
can be directly dissolved in aqueous droplets of the micro-
emulsion. After sphere wall formation, the DOX-containing
water droplet is encapsulated by AlO(OH) (Figure 1). In the
as-prepared suspensions the hollow nanospheres are dense and
do not show leakages or uncontrolled release, which was pre-
viously shown for several examples (e.g. release of rhodamine
from AlO(OH) hollow nanospheres, release of thiourea from
ZnO hollow nanospheres, release of isoniacid from Fe2O3 hol-
low nanospheres).[13,15] Following this strategy, doxorubicin
(20 mg) was encapsulated in AlO(OH) hollow spheres (1 g).
Successful DOX incorporation can be qualitatively detected
based on the strong orange-red color of DOX@AlO(OH),
whereas non-filled AlO(OH) hollow spheres are colorless (Fig-
ure 2a). Furthermore, the presence of DOX was proven by op-
tical spectroscopy (UV/Vis, Figure 2b) and Fourier-transform
infrared spectroscopy (FT-IR, Figure 2c and Supporting Infor-
mation). Both show the characteristic absorption of DOX for
DOX@AlO(OH), which is similar to pure DOX (Figure 2).
Certain shifts of the respective absorptions between nanocon-
tainers and free DOX can be ascribed to the interaction of
DOX with the AlO(OH) sphere wall. Finally, the DOX con-
centration in the nanocontainers was determined based on
optical spectra and by quantification via the Kubelka-Munk
approach (Figure S2 and Table S2, Supporting Information),
resulting in 22 mg DOX per 1 g of nanocontainers, which-
Figure 2. Presence of DOX in DOX@AlO(OH) nanocontainers: (a)
Photos of powder samples; (b) UV/Vis spectra; (c) FT-IR spectra (non-
filled AlO(OH) hollow spheres and pure DOX as references) (quantifi-
cation of DOX content: Table S1, Figure S2, Supporting Information).
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within the significance of the method-is in good accordance
with the DOX amount introduced as a starting material.
The synthesis of the DOX@AlO(OH) nanocontainers was
adjusted to meet the demands of the biomedical context:[13,15]
after purification the DOX@AlO(OH) nanocontainers
(75 μg·mL–1) were redispersed in aqueous dextran
(4 mg·mL–1). Dextran coatings were often applied in the case
of iron oxide nanoparticles,[16] which can be considered to be
chemically similar to aluminum oxide. Dextran-coated
DOX@AlO(OH) nanocontainers indeed showed an improved
membrane penetration and cell uptake in comparison to non-
coated nanocontainers. Additional aspects, such as the size,
agglomeration, surface charge or type of cell, are of course
also relevant.[17] With a final DOX concentration of
1.5 μg·mL–1, the applied concentration is at the lowest range
of DOX concentrations used in other studies,[1–3,18] which is
not necessarily disadvantagous if sufficient activity is com-
bined with low side effects.
2.2 In vitro Studies
To investigate cell uptake and treatment related toxicity, hu-
man liver carcinoma cells (HepG2) and cervical cancer cells
(HeLa) were incubated with DOX@AlO(OH) nanocontainers
during cultivation. First, confocal laser scanning microscopy
(CLSM) was used to analyze the biocompatibility of
DOX@AlO(OH) qualitatively. DOX@AlO(OH)-treated
HepG2 and HeLa cells do not show striking aberrations in
morphology, and proliferation seems unimpaired within the in-
vestigated time frame of 24 hours (Figure 3; Figure S3a, Sup-
porting Information). Based on the intense red fluorescence of
doxorubicin (λem = 590 nm, λexc = 488 nm, argon laser),[19]
CLSM can also be used to monitor the uptake of
DOX@AlO(OH) into cells. The intracellular distribution of
DOX@AlO(OH) is shown in Figure 3 (Figure S3a, Supporting
Figure 3. Cell uptake and fluorescence of DOX@AlO(OH) nanocon-
tainers in human liver carcinoma cells (HepG2 cell line) according to
CLSM images (argon laser with λexc = 488 nm, λem = 590 nm; scale
bar is 25 μm).
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Information). In comparison to cells treated with free DOX
(Figure S3b, Supporting Information), DOX@AlO(OH)-
treated cells display a more granular fluorescence, most likely
caused by moderate clustering of the DOX@AlO(OH) nano-
containers. Some larger clusters might not be internalized due
to steric hindrance but remain attached to the cell surface,
whereas the majority of the nanocontainers is evenly distrib-
uted within perinuclear regions (Figure 3; Figure S3a, Support-
ing Information).
Additionally, the cytotoxicity of DOX@AlO(OH) nanocon-
tainers was quantified based on MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) assays (Figure 4 and
Figure S4, Supporting Information). For this purpose, HepG2
and HeLa cells were incubated for 72 h with different concen-
trations of DOX@AlO(OH) nanocontainers. Treating cells
with DOX@AlO(OH) portions to obtain 0.25 to 1 μM of DOX
highly impairs cell viability, which drops to around 20%, gen-
erating an LD50  0.25 μM within the statistical error (Fig-
ure 4, Figure S4: red bars, Supporting Information). Obviously,
DOX was successfully delivered into the cell and released
from the dense AlO(OH) shell within the time frame of
72 hours, making the cells undergo apoptosis and necrosis. If
free doxorubicin was administered in the same concentration
range as a control, in contrast, cells are less affected and the
LD50 is around 0.5 μM (Figure 4, Figure S4: brown bars, Sup-
porting Information). For a further crucial control, cells were
treated with non-filled AlO(OH) to exclude toxic effects from
the delivery system itself (Figure 4, Figure S4: green bars,
Supporting Information). Empty AlO(OH) hollow nanospheres
proofed to be highly biocompatible with almost normal cell
viability (90%). Here, it needs to be noticed that the cell via-
bility is even less affected than after treatment with massive
AlO(OH) nanoparticles (Figure 4, Figure S4: light green bars,
Supporting Information).
Figure 4. In vitro cytotoxicity of DOX@AlO(OH) nanocontainers in
HepG2 cells using MTT assays with non-filled AlO(OH) nanocontai-
ners, massive AlO(OH) nanoparticles and free DOX as controls (statis-
tical error bars calculated from triplicates of n = 8; significance deter-
mined according to student’s t-test with p  0.05).
2.3 In vivo Studies
To validate the results gained in in vitro experiments,
in vivo studies were performed to determine the effect of
DOX@AlO(OH) on the progression of primary tumors and
metastasis. This study was conducted in a breast cancer BALB/
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c mouse model, where murine 4T1 breast-adenocarcinoma
cells (1106 cells per mL) were orthotopically implanted into
the mammary fat pad of 8–12 weeks old female BALB/c-mice.
In fact, this 4T1 cell line is an excellent system for investiga-
ting human breast cancer as it provides the opportunity to
study the agent’s impact not only on solid tumors but also on
metastasis to organs affected in human breast cancer.
Eleven days after tumor induction, mice were intraperitone-
ally injected into the abdominal cavity with DOX@AlO(OH)
nanocontainers (0.015 mg DOX/kg of body weight, in water).
Injections of free DOX (2.5 mg·kg–1 of body weight, in PBS
buffer) and physiological saline (DPBS) were used as positive
and negative controls. It is to be noted that DOX is typically
applied in doses of up to 20 mg·kg–1 of bodyweight in the
literature.[20] Here, we use the lowest dose for anti-tumor treat-
ment with free DOX that was found in the literature
(2.5 mg·kg–1 of body weight). This concentration is neverthe-
less significantly higher than the DOX concentration available
in the DOX@AlO(OH) nanocontainers (0.015 mg DOX per kg
of body weight). The injections were performed trice a week
for a total of seven doses (Figure 5). Throughout the experi-
ment, body weight and volume of tumors were assessed (Fig-
ure 5; Figure S5, Supporting Information).
Figure 5. Scheme of animal treatments (1106 4T1 cells inoculated
into the mammary fat pad of BALB/c mice) and anti-tumor effect of
DOX@AlO(OH) nanocontainers: tumor volumes as function of time
for treatment with DOX@AlO(OH) nanocontainers (70.015 mg
DOX/kg of bodyweight), free DOX (2.5 mg·kg–1 of bodyweight), and
DPBS [each value represents the mean of n = 8 animals in the respec-
tive group; Figure S6 (Supporting Information) shows details with one
graph per animal].
Mice did not show any abnormality or increased mortality
during the study as indicated by their constant bodyweight
(Figure S5, Supporting Information) and unaltered behavior.
The tumors of mice increased in size from day 1 to 21
in all groups (Figure 5). However, tumor growth in
DOX@AlO(OH)-treated mice is significantly impaired (Fig-
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ure 5: yellow graph) as compared to the group treated with
physiological saline (Figure 5: blue graph). After three weeks,
primary tumors in mice treated with DOX@AlO(OH) nano-
containers are significantly smaller (volumes up to 3 cm3) as
compared to the tumors in the control groups treated with
DPBS or free DOX (volumes up to 6 cm3). Additionally, tu-
mors of mice treated with DOX@AlO(OH) nanocontainers did
not break up cortically as observed in both control groups.
Interestingly, statistical spreading of tumor volumes is also
more narrow within the DOX@AlO(OH) group (Figure S6,
Supporting Information). The surprisingly high tumoricidal ef-
ficacy of the DOX@AlO(OH) nanocontainers can be ascribed
to the well-accepted particle accumulation in tumor tissue due
the enhanced permeability and retention (EPR) effect.[21] As
the nanoparticles are accumulated in the tumor, slow dissol-
ution of the AlO(OH) nanocontainers under physiological con-
ditions results in a slow release of DOX directly into the tumor
tissue. As a result, the maximum DOX concentration can be
low and nevertheless guarantees for a significant effect. More-
over, advanced multistep syntheses and materials of high com-
plexity of materials can be avoided.
In addition to the influence of DOX@AlO(OH) nanocontai-
ners on primary tumors, DOX-related side effects and impacts
on metastasis were studied as well. To this concern, blood was
collected via cardiocentesis at the end of the study, namely just
before sacrification of mice. Mice treated with DOX@filled
AlO(OH) nanocontainers show a similar blood count to DPBS-
treated control mice (Table S2, Supporting Information). In
contrast, treatment with free DOX caused well-recognized side
effects of chemotherapy, such as injury of liver, kidney and
other organs (elevated levels of lipase and low levels of cal-
cium, alkaline phosphatase and globulins; Table S2).[3,4,18,22]
For free DOX, it can be concluded that side effects manifest
already at low concentrations (2.5 mg·kg–1, 4.6 μmol·kg–1 of
bodyweight).
In contrast, DOX@AlO(OH) nanocontainers display high
activity even in a low dose range of 0.015 mg DOX/kg of
bodyweight without any significant side effects (according to
blood counts, Table S2, Supporting Information). These find-
ings can be ascribed to the rapid metabolic decomposition of
free DOX in the body before reaching the cancer cells. In order
to achieve similar activity in the tumor, significantly higher
concentrations of free DOX (2.5 mg·kg–1 of body weight) are
obviously necessary in comparison to DOX@AlO(OH) nano-
containers, which accumulate in the tumor tissue with their
full DOX load (0.015 mg·kg–1 of body weight). Against the
background of a severe tumor disease, the use of nanocontai-
ners containing aluminum would most probably also be ac-
ceptable in view of the connection with Alzheimer’s disease,
which is often discussed but still not finally confirmed.[23]
Furthermore, the effect of DOX@AlO(OH) nanocontainers
on metastatic spreading towards lymph nodes and lung was
evaluated histologically. Hematoxylin/eosin stainings of 7 μm
sections revealed that lungs of DPBS-treated mice contain
multiple tumor nodules, harboring cells with abnormal mor-
phology and polyploid nuclei (representative HE-stainings in
Figure 6a). In contrast, metastatic foci were significantly re-
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duced in organs of mice treated with DOX@AlO(OH) nano-
containers, indicating an anti-metastatic effect. For validation
the volume of ipsilateral lymph nodes was assessed (Figure 6b
and c). Here, the volume of lymph nodes draining the tumor
is remarkably smaller in DOX@AlO(OH)-treated mice as
compared to animals treated with DPBS, likewise substantiat-
ing the anti-metastatic potential of DOX@AlO(OH) nanocon-
tainers.
Figure 6. Anti-metastatic effect of DOX@AlO(OH) nanocontainers
with: (a) Qualitative histological analysis of lymph nodes and lungs
(haematoxylin- and eosin-stained histological sections) showing me-
tastases of DPBS-treated mice in lymph nodes and lung (lung metasta-
ses also macroscopically visible-see frame), and quantification of the
lymph-node metastasis by measuring the mean volumes of ipsilateral
(b) axillary and (c) inguinal lymph nodes (n = 8; error bars indicate
the statistical error).
3 Conclusions
Doxorubicin-filled boehmite nanocontainers
[DOX@γ-AlO(OH)] are shown as drug-delivery system for
cancer treatment. The AlO(OH) nanocontainers (mean dia-
meter of 40 nm, wall thickness of 10 nm) are filled with DOX
(20 mg·g–1) via a straightforward microemulsion strategy. Af-
ter dextran coating the nanocontainers are colloidally stable
and show fast cell uptake. Cell uptake, fluorescence detection
and systemic nanocontainer-related toxicity are evaluated
based on human liver carcinoma cells (HepG2) and human
cervical cancer cells (HeLa) as in vitro models. The compari-
son with non-filled AlO(OH) nanocontainers and free DOX
proves the biocompatibility of the AlO(OH) nanocontainers
and the encapsulation of DOX in DOX@AlO(OH).
In vivo studies based on an orthotopic breast cancer
BALB/c mouse model prove the activity of DOX@AlO(OH)
even at low concentration (0.015 mg DOX per kg of body
weight) in comparison to free doxorubicin (2.5 mg DOX per
kg of body weight). Very promising anti-tumor and anti-meta-
static effects are observed. Notably, significant anti-tumor and
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anti-metastatic effects are observed at low DOX concentration
and without observing typical DOX-related severe side effects.
Due to the enhanced permeability and retention (EPR) effect,
the DOX@AlO(OH) nanocontainers are accumulated in solid
breast tumors without the need of advanced and complex mate-
rials, including the necessity of antibodies.
In sum, DOX@AlO(OH) nanocontainers show promising
effects on the primary tumor and on metastasis as well as in
combination with low side effects. These findings can be as-
cribed to the collection of the nanocontainers in the tumor tis-
sue, which is driven by the EPR effect. Thereafter, the nano-
containers are slowly dissolved and can release all DOX into
the tumor. With this strategy, on the one hand, unspecific bio-
degradation of DOX and side effects can be reduced. Due to
the metabolic dissolution of the AlO(OH) nanocontainers,
moreover, fast clearance from the body can be expected, which
may help avoiding negative long-term effects (e.g. as recently
reported for SiO2). Detailed studies on, e.g., drug release, biod-
istribution and body clearance need to be performed next to
explore dose-activity relations and to obtain suitable dosing
schemes.
4 Experimental Section
4.1 Synthesis of DOX@AlO(OH) Nanocontainers
In general, the synthesis of nanoscale AlO(OH) nanocontainers follows
our previously reported microemulsion approach.[13] The micellar sys-
tem was established by n-hexane as the non-polar dispersant phase, a
mixture of methanol and water (1 : 1) as the polar phase. Cetyltrimeth-
ylammonium bromide (CTAB) was used as the surfactant and 1-hexa-
nol as the co-surfactant (Figure 1). Doxorubicin (9.5 mg, doxorubicin
hydrochloride, 98–102%, Sigma–Aldrich) were dissolved in the meth-
anol-water mixture and added as part of the polar phase of the micro-
emulsion system. The presence of DOX is directly perceptible via its
strong orange-red color. After establishing the microemulsion system
and certain time of equilibration, Al(sec-OC4H9)3 (246 mg, Aldrich,
97 %) was added to the hexane phase of the equilibrated, transparent
orange w/o-microemulsion. In a period of 12 hours, the alkoxide was
left to react at the water-to-oil phase boundary of the microemulsion
system (Figure 1). The as-prepared DOX@AlO(OH) nanocontainers
were collected via centrifugation. Thereafter, they were purified by
sequential resuspension/centrifugation in/from 2-propanol and water.
Finally, the DOX@AlO(OH) nanocontainers were redispersed in aque-
ous dextran (DOX@AlO(OH) with 0.075 mg/mL; dextran with
4 mg·mL–1).
4.2 HepG2 and HeLa Cells
For confocal microscopy, 2104 HepG2 (human liver carcinoma) or
HeLa (human cervix carcinoma) cells were seeded into each well of
a 8-well microslide Ibitreat from (IBIDI, Martinsried, Germany) and
cultured in Dulbecco’s modified Eagle’s medium, high glucose,
(DMEM, Invitrogen, Karlsruhe, Germany) supplemented with 10%
fetal calf serum (FCS, PAA) and 1 U·mL–1 penicillin/streptomycin at
37 °C, 5% CO2. Confocal microscopy was performed with a Leica
SP5 device (DMI6000).
MTT assays were performed to determine the cell viability (Figure 4).
The yellow tetrazolium compound 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
Journal of Inorganic and General Chemistry
Zeitschrift für anorganische und allgemeine Chemie
ARTICLE
phenyltetrazolium bromide used in this assay was reduced to purple
formazan by mitochondrial enzymes and quantified photometrically.
As this reaction was limited to metabolically active cells, the amount
of formazan is directly correlated with the cell viability. HepG2 and
HeLa cells were seeded on 96-well plates at a density of 1104 cells/
well and cultivated at 37 °C and 5% CO2. Cells were incubated with
DOX@AlO(OH) nanocontainers in diverse concentrations for 1–3 d.
Controls were treated with 5 μL Triton X-100. Afterwards, 15 μL of
MTT solution (dye solution for MTT test, Promega) were added to
each well and incubated for 1.5 h. The reaction was stopped by ad-
dition of 100 μL of lysis buffer. After 1.5 h, the absorbance of the
converted dye was measured in a photometer (ultra microplate reader
ELx808, BioTEK Instruments) at a wavelength of 595 nm.
4.3 Orthotopic Breast Cancer BALB/c Mouse Model
4T1 cells were maintained in DMEM medium supplemented with 10%
FCS and 1% penicillin/streptomycin at 37 °C in a humidified incu-
bator with 5% CO2. 1106 cells in 100 μL of PBS were injected
orthotopically into the mammary fat pad of 8–12 weeks old female
BALB/c mice. Prior to injection, cells were tested for mycoplasma
with the VenorGeM® Mycoplasma Detection Kit. 11 days after tumor
induction, mice were randomized into four experimental groups (four
mice per group). Mice were treated intraperitoneally with dextran-
coated DOX@AlO(OH) nanocontainers (0.015 mg DOX/kg of bod-
yweight) trice a week for a total of seven doses. Control groups were
treated with PBS or doxorubicin (2.5 mg·kg–1 of bodyweight) (Fig-
ure 5; Figure S6, Supporting Information). Animals were killed and an
autopsy was performed when they became moribund or when tumors
grew to the German legal limit.
The tumor growth was monitored by measuring the tumor diameters
with calipers twice a week. The tumor volume was calculated using
the formula 4/3·π·a·b·c (ellipsoid). The treatment-related toxicity was
determined by mouse weights weekly. Before the end of the study,
26 days after tumor induction, blood was collected via cardiocentesis
(cf. Table S2, Supporting Information). Tumor, inguinal and auxiliary
lymph nodes were dissected, weighed and measured in size (Figure 6).
The lung was macroscopically examined for the occurrence of metasta-
ses. Lung, tumor and lymph nodes were fixed overnight in 3.7 % par-
aformaldehyd, embedded in paraffin and cut into sections for histologi-
cal staining with hematoxylin and eosin. Animal procedures were ap-
proved by the regional government on animal experimentation in Ger-
many: 35–9185.81/G-5/10.
Supporting Information (see footnote on the first page of this article):
More data related to the analytical tools, material characterization, the
in vitro studies and in vivo studies can be found in the Supporting
Information.
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